You are on page 1of 4

U Illinois Healthcare and Life Sciences Update | Enewsletter | Illinois

4/19/13 10:44 AM

Spring 2013 Edition (view online) Welcome to the Office of Technology Management's first e-newsletter for healthcare and life science activities! Every quarter we'll deliver a summary of the newest technologies, research and startup activity coming out of the University of Illinois UrbanaChampaign - straight to your inbox. **Be sure to stop by the Academic Zone at the 2013 BIO International Convention and meet some of the OTM staff!**

TIME Magazine: UIUC Startup mc10 Named One of TIMEs 10 Ideas That Make a Difference in 2013: Wear Your Doctor Technology Review*: Electronic Sensors Printed Directly on the Skin Chemical & Engineering News: American Chemical Society Awards E.J. Corey Award to Professor Martin Burke for the most powerful set of synthetic reagents for organic synthesis disclosed in the past five years. R&D Magazine*: World's Most Sensitive Plasmon Resonance Sensor Inspired by Ancient Roman Cup Chemical & Engineering News*: Ringing in New Drug Candidates USA Today: Interview with NFL Quarterback Matt Hasselbeck at Consumer Electronics Show regarding UIUC startup mc10s CheckLight product BBC News: Rat Heart Cells Help Create Walking 'Bio-Bots' Science-Business eXchange*: Inhibitors of UPPS Treat MRSA *These articles feature information from the publications below.

http://illinois.edu/emailer/newsletter/35491.html

Page 1 of 4

U Illinois Healthcare and Life Sciences Update | Enewsletter | Illinois

4/19/13 10:44 AM

StemPar Sciences The University of Illinois at Urbana-Champaign and the University of Texas Southwestern Medical Center have entered into a license agreement through which StemPar Sciences plans to develop cancer therapeutics based on compounds designed by Professors Paul Hergenrother and David Boothman. Read more here. Genalyte has licensed technologies developed in the laboratory of Professor Ryan Bailey for novel signal enhancement methods for use in the companys multiplexed protein detection systems. Vertex Pharmaceuticals has executed a research use license for Nanodisc technologies developed by Professor Stephen Sligar enabling the study of membrane proteins in native-like environments. Vanquish Oncology, a University of Illinois startup based on small molecule compounds targeting molecular defects in specific cancer cells developed by Professor Paul Hergenrother, has raised a $2 million Series A round. mc10 Inc., a University of Illinois startup based on technologies in flexible, stretchable electronics developed by Professor John Rogers, has raised $10 million from medical device giant Medtronic, an unnamed consumer health firm, and previous investors. Read more here. Immuven Inc. - ImmuVen was awarded a Phase II Small Business Innovation Research grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus. Read more here. Oxford Nanopore Technologies, Ltd. has licensed solid state nanopore technologies developed by the groups of Professors Jean-Pierre Leburton, Aleksei Aksimentiev, and Rashid Bashir for DNA sequencing efforts. Read more here.

University of Illinois at Urbana-Champaign licenses Nanodisc technologies to multiple pharmaceutical companies and makes membrane scaffold proteins available through Sigma-Aldrich. Membrane proteins play a critical yet challenging role in pharmaceutical research and development. They account for the majority of known therapeutic targets yet are extremely difficult to study and manipulate outside of their native membranes. Nanodisc systems, developed by Professor Stephen Sligar of the University of Illinois at Urbana-Champaign, address this challenge enabling membrane proteins to be isolated and protected within phospholipid bilayers that mimic their natural membrane. The systems have been widely used since their introduction, applied to biomolecules such as enzymes, receptors, transporters, and pumps and channels. Preserving full functionality of the proteins, Nanodiscs offer significant advantages in homogeneity, stability, ability to modify, and access for binding entities over other commonly used solubilization methods. The centerpiece of more than 200 scientific publications from a wide range of groups, Nanodiscs serve as (i) powerful discovery tools allowing membrane proteins to be assayed by a spectrum of bioanalytical techniques, (ii) therapeutic delivery systems that are immunologically neutral, and (iii) means to identify unknown membrane proteins to discover new pharmaceutical targets. Recently, the University of Illinois at Urbana-Champaign has entered into license agreements with several pharmaceutical companies empowering them to use Nanodiscs in their research and development efforts. Philip Tagari, Vice President of Research of Amgen Inc., one of the licensees, stated, Delivery of complex biologicals suffers from the lack of a single platform for diagnosis, drug discovery, and therapeutic delivery. We have found Nanodiscs to be a powerful method for handling membrane proteins and an important tool in our laboratories . In addition, through a commercial license with the University, Sigma-Aldrich is selling two of the most commonly used membrane scaffolds for Nanodiscs. Our customers find Nanodiscs to be an increasingly general component of their toolkit in the study of membrane proteins, said Robert Gates, Market Segment Manager for SigmaAldrich. By offering these scaffolds, Sigma aims to facilitate diagnostic and therapeutic advances not previously possible. The recent license agreements highlight the University of Illinois strategy to enable broad adoption of the technology.
http://illinois.edu/emailer/newsletter/35491.html Page 2 of 4

U Illinois Healthcare and Life Sciences Update | Enewsletter | Illinois

4/19/13 10:44 AM

Nanodiscs provide a unique and powerful system for membrane proteins, allowing diverse capabilities from characterization to drug discovery to development of new therapeutic vehicles, described Lisa Dhar of the Universitys Office of Technology Management. We view wide use as critical to fully exploiting the potential of this valuable approach.

New single-molecule assay for the detection of DNA methylation - Detection and Quantification of Methylation in DNA using Solid-State Nanopores. Scientific Reports. March 2013. DNA catalysts do the work of protein enzymes - Catalytic DNA with phosphatase activity. Proc Natl Acad Sci. March 2013. Multiplexed screening of protein interactions - Interfacing Lipid Bilayer Nanodiscs and Silicon Photonic Sensor Arrays for Multiplexed ProteinLipid and ProteinMembrane Protein Interaction Screening. Anal. Chem. Feb 2013. Study may explain how human parasite survives for so many years Adult somatic stem cells in the human parasite Schistosoma mansoni. Nature. Feb 2013. Building a biochemistry lab on a chip - Ultralocalized Thermal Reactions in Sub-Nanoliter Droplets-in-Air. Proc Natl Acad Sci. Feb 2013. Tweaking natural products rings to create better compound libraries - A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nature Chemistry. Jan 2013. 3D customizable cell culture platforms compatible with standard optical and fluorescence microscopy - CellLaden Hydrogels in Integrated Micro''uidic Devices for Long-Term Cell Culture and Tubulogenesis Assays. Small. January 2013. New compound overcomes drug-resistant Staph infection - Antibacterial drug leads targeting isoprenoid biosynethsis. Proc Natl Acad Sci. Jan 2013. Odd biochemistry produces lethal bacterial toxin - The Sequence of the Enterococcal Cytolysin Imparts Unusual Lanthionine Stereochemistry. Nat Chem Bio. Jan 2013. Worlds most sensitive plasmon resonance sensor - Colorimetric Plasmon Resonance Imaging Using Nano Lycurgus Cup Arrays. Advanced Optical Materials. Jan 2013. Intraoperative imaging to reduce high rate of reexcision - Intraoperative assessment of tumor margins with a new optical imaging technology: A multi-center, randomized, blinded clinical trial. Cancer Research. Dec 2012 Stem-cell approach shows promise for Duchenne muscular dystrophy- Injection of Vessel-Derived Stem Cells Prevents Dilated Cardiomyopathy and Promotes Angiogenesis and Endogenous Cardiac Stem Cell Proliferation in mdx/utrn/ but Not Aged mdx Mouse Models for Duchenne Muscular Dystrophy. Stem Cells Trans Med. Dec 2012.

Anti-Infectives TF12205 Magnetic Hyperthermia Treatment Against Parasitic Infection TF12190 Antibacterial Drug Leads Targeting Isoprenoid Biosynthesis TF12184 Chemo-Immunotherapeutic Anti-Malarials Targeting Isoprenoid Biosynthesis Diagnostics TF13009 A Microfluidic Device for the Formlation of Protein-Containging Lipidic Mesophases and Crystallization of a Membrane
http://illinois.edu/emailer/newsletter/35491.html Page 3 of 4

U Illinois Healthcare and Life Sciences Update | Enewsletter | Illinois

4/19/13 10:44 AM

TF13004 Colorometric Plasmon Resonance Imaging of Biomolecules TF12195 Glucose Sensors Suitable for Continuous Glucose Monitoring TF12188 Markers for the Detection of Brain Cancer Types TF12167 Electrically Based Viral Detection in a Biochip Hematology TF13017 Polyphosphate Nanoparticles for treatment of external and internal Hemorrhage Imaging TF13011 Polymeric Microfluidic Continuous Flow Reactor for Investigation of Protein Structure and Function with Fourier Transform Infrared (FTIR) Spectroscopy TF12194 Integrated Microfluidic Platform for Long-Term Cell-Biomaterial Studies in Three-Dimensions TF12170 Dispersion-Relation Fluorescence Spectroscope Molecular Tools TF13014 Interfacing Lipid Bilayer Nanodiscs and Silicon Photonic Sensor Arrays for Multiplexed Protein-Lipid and Protein-Membrane Protein Interaction Screening TF12191 RNAi-assisted Genome Engineering for rapid and diverse mutagenesis of Yeast TF12186 Method for high-throughput synthesis of TAL Effector DNA binding domains Nutrition TF12192 Whole Cell Biosynthesis of a Functional Human Milk Oligosaccharide (HMO) using Engineered E. Coli Therapeutics (Oncology & Other) TF12201 Synthesis and Anticancer Activity of Epipolythiodiketopiperazine Alkaloids TF12039 Small molecule therapeutic agents for the treatment of Myotonic Dystrophy

Get in touch with us! Email Assistant Director, Life Sciences Lisa Dhar, Ph.D. or Technology Manager Jen Rice, Ph.D.

Subscribe Unsubscribe

Twitter

Facebook

LinkedIn

Google+

Website

http://illinois.edu/emailer/newsletter/35491.html

Page 4 of 4